5VA Stock Chart & Stats
€50.00
€2.00(2.45%)
At close: 4:00 PM EST
€50.00
€2.00(2.45%)
Day’s Range― - ―
52-Week Range€24.80 - €51.00
Previous CloseN/A
Volume0.00
Average Volume (3M)39.00
Market Cap
€7.21B
Enterprise Value€7.17B
Total Cash (Recent Filing)€1.74B
Total Debt (Recent Filing)€116.30M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Aug 12, 2026EPS Estimate
-1.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.89
Shares Outstanding144,397,670
10 Day Avg. Volume108
30 Day Avg. Volume39
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio-9.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€101.70Price Target Upside103.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-7.26
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage And Sizeable Equity BaseA low-debt, equity-rich balance sheet provides durable financial flexibility for a development-stage biotech. It increases runway capacity to fund clinical programs, supports non-dilutive partnerships or contract manufacturing deals, and reduces bankruptcy risk during multi-year development cycles.
Focused Clinical-stage Vaccine Pipeline (pneumococcal)A clear strategic focus on higher-valency pneumococcal vaccines aligns the company with an enduring global public-health need. Specialized pipeline positioning can create differentiated market entry opportunities and sustain long-term value if clinical success leads to licensing or commercialization partnerships.
Governance Continuity And Experienced Board AdditionRe-election of directors plus appointment of an experienced independent director strengthens oversight and strategic capabilities, especially in supply/manufacturing. Stable governance reduces execution risk for complex clinical programs and aids credibility with partners and regulators over the medium term.
Bears Say
Zero Revenue And Accelerating Net LossesPersistent zero revenue coupled with rapidly widening losses is a fundamental constraint for sustainability: it indicates the company remains pre-commercial, increases reliance on external funding, and raises execution risk if clinical timelines or trial outcomes delay potential revenue generation.
Escalating Operating Cash Burn And Negative Free Cash FlowMaterial and growing negative operating cash flow and free cash flow are structural risks for a clinical-stage firm: they shorten runway, necessitate frequent financings that can dilute equity, and may force partnerships or program prioritization that alter long-term strategy and optionality.
Negative Returns On Equity; Capital Funding LossesA substantially negative ROE shows invested capital is not producing returns and highlights long lead times to commercialization. This metric implies continued investor reliance to back R&D, increasing scrutiny on program viability and making it harder to attract non-dilutive funding absent clear clinical de‑risking.
Vaxcyte News
5VA FAQ
What was Vaxcyte, Inc.’s price range in the past 12 months?
Vaxcyte, Inc. lowest stock price was €24.80 and its highest was €51.00 in the past 12 months.
What is Vaxcyte, Inc.’s market cap?
Vaxcyte, Inc.’s market cap is €7.21B.
When is Vaxcyte, Inc.’s upcoming earnings report date?
Vaxcyte, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 34 days.
How were Vaxcyte, Inc.’s earnings last quarter?
Vaxcyte, Inc. released its earnings results on May 06, 2026. The company reported -€2.017 earnings per share for the quarter, missing the consensus estimate of -€1.559 by -€0.458.
Is Vaxcyte, Inc. overvalued?
According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued.
Does Vaxcyte, Inc. pay dividends?
Vaxcyte, Inc. does not currently pay dividends.
What is Vaxcyte, Inc.’s EPS estimate?
Vaxcyte, Inc.’s EPS estimate is -1.8.
How many shares outstanding does Vaxcyte, Inc. have?
Vaxcyte, Inc. has 144,397,670 shares outstanding.
What happened to Vaxcyte, Inc.’s price movement after its last earnings report?
Vaxcyte, Inc. reported an EPS of -€2.017 in its last earnings report, missing expectations of -€1.559. Following the earnings report the stock price went down -5.31%.
Which hedge fund is a major shareholder of Vaxcyte, Inc.?
Currently, no hedge funds are holding shares in DE:5VA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vaxcyte Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€101.70 (103.41% Upside)
€101.70 (103.41% Upside)
Blogger Sentiment
Bullish
DE:5VA Sentiment 70%
Sector Average 69%
Sector Average 69%
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.59%
12-Months-Change
Fundamentals
Return on Equity
-32.51%
Trailing 12-Months
Asset Growth
-0.88%
Trailing 12-Months
Company Description
Vaxcyte, Inc.
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
5VA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a strongly positive operational and clinical momentum story: robust balance sheet extended by a ~$600M financing, completion of a commercial-scale manufacturing facility on time and on budget, initiation of three pivotal/Phase III adult OPUS trials with expected top-line readouts over the next 18 months, completed infant enrollment (900 infants), and resumption of the Group A Strep program. Offsetting risks are mostly predictable near-term impacts from materially higher R&D and manufacturing expenses in 2026, serotype-level regulatory uncertainties (and the idiosyncratic challenge of serotype 3), and a competitive landscape with other PCV developers. Overall, the highlights—particularly cash runway, manufacturing completion, and late-stage clinical progress—materially outweigh the lowlights, which are manageable programmatic and financial execution risks.View all DE:5VA earnings summaries5VA Stock 12 Month Forecast
Average Price Target
€101.70
▲(103.41% Upside)
Technical Analysis
Options Prices
Currently, No data available
---